

MANKIND PHARMA FZ-LLC

**FINANCIAL STATEMENTS AND REPORTS
YEAR ENDED 31 MARCH 2023**

MANKIND PHARMA FZ-LLC

FINANCIAL STATEMENTS AND REPORTS YEAR ENDED 31 MARCH 2023

CONTENTS	PAGE
DIRECTORS' REPORT	1
INDEPENDENT AUDITOR'S REPORT	2– 4
STATEMENT OF FINANCIAL POSITION	5
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	6
STATEMENT OF CHANGES IN EQUITY	7
STATEMENT OF CASH FLOWS	8
NOTES TO THE FINANCIAL STATEMENTS	9 – 28

MANKIND PHARMA FZ-LLC

DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2023

The directors submit their report and financial statements for the year ended 31 March 2023. We approve the financial statements and confirm that we are responsible for these, including selecting the accounting policies and making the judgments underlying them. We confirm that we have made available all relevant accounting records and information for their compilation.

Results and dividends

The loss for the year amounted to AED 1,891,911. The directors do not recommend any dividend for the year ended 31 March 2023.

Review of the business

The Company is licensed for import, re-export, marketing, sales promotion, storage and support services of therapeutic products.

Legal and regulatory requirements

The Company has complied with the applicable provisions of the Dubai Creative Clusters Private Companies Regulations, 2016.

Events since the end of the year

There are no significant events since the end of the year.

Shareholder and the interest in share capital

The Shareholder at 31 March 2023 and its interest as at that date in the share capital of the Company was as follows:

Name	31 March 2023	
	No. of shares	AED
Mankind Pharma Limited, India	24,600	24,600,000
	<u>24,600</u>	<u>24,600,000</u>

Independent auditor

PKF were appointed as independent auditor for the year ended 31 March 2023 and it is proposed that they be re-appointed for the year ending 31 March 2024.

Director
22 May 2023



INDEPENDENT AUDITOR'S REPORT

To the Shareholder of **MANKIND PHARMA FZ-LLC**

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **MANKIND PHARMA FZ-LLC** (the "Company"), which comprise the statement of financial position as at 31 March 2023, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 31 March 2023, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in the UAE, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. Other information comprises the Directors' report, which we obtained prior to the date of this auditor's report. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we concluded that there is a material misstatement of the other information, we are required to report that fact. We have nothing to report in this regard.

continued...